Clinical Trials Logo

Clinical Trial Summary

Use of dexmedetomidine in pituitary tumor resection surgery as adjuvant drug and its relation to cortisol levels during postoperative period.


Clinical Trial Description

Transsphenoidal resection of pituitary tumors is the neurosurgical procedure of choice to remove most of the tumors of the sellar region. Sometimes the intervention produces dysfunction of the hypothalamic-pituitary axis, and although most are transient, the risk associated with post-operative hypocortisolism determines its evaluation early in the postoperative period and the possibility of steroidal supplementation posteriorly. It is described that dexmedetomidine can be used as an adjuvant drug in this type of surgery being useful in reduction of total consumption of opioids and anesthetic gases, maintain hemodynamic stability and less time to recovery from anesthesia. Due to its sympatholytic effect, dexmedetomidine has been found to alter the intraoperative common neuroendocrine response generating lower levels of cortisol in the postoperative period than patients in which is not used.

The main objective of this study is to evaluate corticosteroid axis response (cortisol and adrenocorticotropic hormone) in patients undergoing transsphenoidal surgery under anesthesia with dexmedetomidine. A single-center randomized double-blind clinical trial will be conducted that will compare two groups of patients, one of which will be given dexmedetomidine (Dex group) and another group who will receive a placebo (control group). In addition the incidence of perioperative complications (nausea, vomiting, diabetes insipidus), intraoperative hemodynamics and patient comfort. The investigators expect that the normal stress response to surgery measured by cortisol and adrenocorticotropic hormone in the postoperative period will be reduced in the dexmedetomidine arm. This effect should be transient and attributed to use of dexmedetomidine and not to surgery. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02549768
Study type Interventional
Source Pontificia Universidad Catolica de Chile
Contact Juan C Pedemonte, MD
Phone 56-2-23543270
Email jcpedemo@gmail.com
Status Recruiting
Phase Phase 4
Start date September 2015
Completion date August 2017

See also
  Status Clinical Trial Phase
Terminated NCT02629549 - Intraoperative Imaging of Pituitary Adenomas by OTL Phase 1
Recruiting NCT02288962 - Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Phase 3
Terminated NCT02743442 - Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland N/A
Completed NCT02632084 - Follow-up Evaluation of Photo-Dynamic Therapy for Pituitary Tumours N/A
Not yet recruiting NCT06282224 - Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery N/A
Recruiting NCT05108064 - Radiomic and Pathomic Study of Pituitary Adenoma Using Machine Learning
Active, not recruiting NCT03665064 - Long Term Outcome Study in Patients With Pituitary Disorders
Recruiting NCT01775332 - Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools N/A
Completed NCT05088252 - Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection N/A
Recruiting NCT02190994 - Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Phase 4